BMRN Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 23.56%. Biomarin Pharmaceutical's return on equity of 8.09% beat Gilead Sciences's return on equity of 2.5%.

Biomarin Pharmaceutical has a consensus price target of $96.72, signalling upside risk potential of 35.22%. On the other hand Gilead Sciences has an analysts' consensus of $111.31 which suggests that it could grow by 3.17%. Given that Biomarin Pharmaceutical has higher upside potential than Gilead Sciences, analysts believe Biomarin Pharmaceutical is more attractive than Gilead Sciences.

Biomarin Pharmaceutical has a beta of 0.330, which suggesting that the stock is 67.009% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.87% to investors and pays a quarterly dividend of $0.79 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Gilead Sciences quarterly revenues of $7.6B. Biomarin Pharmaceutical's net income of $124.9M is lower than Gilead Sciences's net income of $1.8B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 32.51x while Gilead Sciences's PE ratio is 291.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.97x versus 4.72x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of -117.16%. Biomarin Pharmaceutical's return on equity of 8.09% beat Moderna's return on equity of -29.09%.

Biomarin Pharmaceutical has a consensus price target of $96.72, signalling upside risk potential of 35.22%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 57.87%. Given that Moderna has higher upside potential than Biomarin Pharmaceutical, analysts believe Moderna is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.330, which suggesting that the stock is 67.009% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Moderna quarterly revenues of $956M. Biomarin Pharmaceutical's net income of $124.9M is higher than Moderna's net income of -$1.1B. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 32.51x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.97x versus 4.11x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 2.31%. Biomarin Pharmaceutical's return on equity of 8.09% beat Pfizer's return on equity of 8.91%.

Biomarin Pharmaceutical has a consensus price target of $96.72, signalling upside risk potential of 35.22%. On the other hand Pfizer has an analysts' consensus of $31.26 which suggests that it could grow by 22.34%. Given that Biomarin Pharmaceutical has higher upside potential than Pfizer, analysts believe Biomarin Pharmaceutical is more attractive than Pfizer.

Biomarin Pharmaceutical has a beta of 0.330, which suggesting that the stock is 67.009% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.62% to investors and pays a quarterly dividend of $0.43 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are smaller than Pfizer quarterly revenues of $17.8B. Biomarin Pharmaceutical's net income of $124.9M is lower than Pfizer's net income of $410M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 32.51x while Pfizer's PE ratio is 18.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.97x versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 16.72% compared to Biomarin Pharmaceutical's net margin of 24.16%. Biomarin Pharmaceutical's return on equity of 8.09% beat Sarepta Therapeutics's return on equity of 20.83%.

Biomarin Pharmaceutical has a consensus price target of $96.72, signalling upside risk potential of 35.22%. On the other hand Sarepta Therapeutics has an analysts' consensus of $172.01 which suggests that it could grow by 133.67%. Given that Sarepta Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe Sarepta Therapeutics is more attractive than Biomarin Pharmaceutical.

Biomarin Pharmaceutical has a beta of 0.330, which suggesting that the stock is 67.009% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

Biomarin Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomarin Pharmaceutical pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Biomarin Pharmaceutical quarterly revenues are $747.3M, which are larger than Sarepta Therapeutics quarterly revenues of $658.4M. Biomarin Pharmaceutical's net income of $124.9M is lower than Sarepta Therapeutics's net income of $159M. Notably, Biomarin Pharmaceutical's price-to-earnings ratio is 32.51x while Sarepta Therapeutics's PE ratio is 32.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomarin Pharmaceutical is 4.97x versus 4.32x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.